Optimized cocktail of 90Y/177Lu for radionuclide therapy of neuroendocrine tumors of various sizes: a simulation study

被引:1
|
作者
Peer-Firozjaei, Milad [1 ]
Tajik-Mansoury, Mohammad Ali [1 ,2 ]
Geramifar, Parham [3 ]
Ghorbani, Raheb [4 ]
Zarifi, Shiva [1 ]
Miller, Cassandra [5 ,6 ]
Rahmim, Arman [5 ,6 ]
机构
[1] Semnan Univ Med Sci, Fac Med, Dept Med Phys, Semnan 1985717443, Iran
[2] Shahid Beheshti Univ Med Sci SBMU, Sch Med, Dept Biomed Engn & Med Phys, Tehran, Iran
[3] Univ Tehran Med Sci, Shariati Hosp, Res Ctr Nucl Med, Nucl Med Dept, Tehran, Iran
[4] Semnan Univ Med Sci, Dept Epidemiol & Biostat, Fac Med, Social Determinants Hlth Res Ctr, Semnan, Iran
[5] BC Canc Res Inst, Dept Integrat Oncol, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada
关键词
radioisotope cocktail; tumor dosimetry; Lu-177; Y-90; DOSIMETRY; RADIOTHERAPY;
D O I
10.1097/MNM.0000000000001546
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background and objectives There is significant interest and potential in the treatment of neuroendocrine tumors via peptide receptor radionuclide therapy (PRRT) using one or both of Y-90 and Lu-177-labeled peptides. Given the presence of different tumor sizes in patients and differing radionuclide dose delivery properties, the present study aims to use Monte Carlo simulations to estimate S-values to spherical tumors of various sizes with Y-90 and Lu-177 separately and in combination. The goal is to determine ratios of Y-90 to Lu-177 that result in the largest absorbed doses per decay of the radionuclides and the most suitable dose profiles to treat tumors of specific sizes. Material and methods Particle transfer calculations and simulations were performed using the Monte Carlo GATE simulation software. Spherical tumors of different sizes, ranging from 0.5 to 20 mm in radius, were designed. Activities of Lu-177 and Y-90, individually and in combination, were homogeneously placed within the total volume of the tumors. We determined the S-values to the tumors, and to the external volume outside of the tumors (cross-dose) which was used to approximate background tissue. The dose profiles were obtained for each of the different tumor sizes, and the uniformity of dose within each tumor was calculated. Results For all tumor sizes, the self-dose and cross-dose per decay from Y-90 were higher than that from Lu-177. We observed that Lu-177 had the most uniform dose distribution within tumors with radii less than 5 mm. For tumors greater than 5 mm in radius, a ratio of 25% Y-90 to 75% Lu-177 resulted in the most uniform doses. When the ratio of Lu-177 to Y-90 was smaller, the uniformity improved more with increasing tumor size. The cross-dose stayed approximately constant for tumors larger than 15 mm for all ratios of Lu-177 to Y-90. Finally, as the size of the tumor increased, differences in the S-values between different ratios of Lu-177 to Y-90 decreased. Conclusion Our work showed that to achieve a more uniform dose distribution within the tumor, Lu-177 alone is more effective for small tumors. For medium and large tumors, a ratio of Y-90 to Lu-177 with more or less Lu-177, respectively, is recommended.
引用
收藏
页码:646 / 655
页数:10
相关论文
共 50 条
  • [21] Treatment with tandem [90Y]DOTA-TATE an [177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results
    Seregni, E.
    Maccauro, M.
    Coliva, A.
    Castellani, M. R.
    Bajetta, E.
    Aliberti, G.
    Vellani, C.
    Chiesa, C.
    Martinetti, A.
    Bogni, A.
    Bombardieri, E.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (01): : 84 - 91
  • [22] Dual-Isotope Peptide Receptor Radionuclide Therapies with 177Lu and 90Y: Is Quantitative Imaging Possible?
    Miller, C.
    Rahmim, A.
    Celler, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S825 - S825
  • [23] Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska, Jolanta
    Krolicki, Leszek
    Hubalewska-Dydejczyk, Alicja
    Mikolajczak, Renata
    Sowa-Staszczak, Anna
    Pawlak, Dariusz
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (10) : 1788 - 1797
  • [24] Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Jolanta Kunikowska
    Leszek Królicki
    Alicja Hubalewska-Dydejczyk
    Renata Mikołajczak
    Anna Sowa-Staszczak
    Dariusz Pawlak
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 1788 - 1797
  • [25] Implementation of dose point kernel (DPK) for dose optimization of 177Lu/90Y cocktail radionuclides in internal dosimetry
    Peer-Firozjaei, Milad
    Tajik-Mansoury, Mohammad Ali
    Geramifar, Parham
    Parach, Ali Asghar
    Zarifi, Shiva
    APPLIED RADIATION AND ISOTOPES, 2021, 173 (173)
  • [26] Skin dose saving of the straff following the acquisition of an automated multidoseinjection system in 90Y/177Lu peptide receptor radionuclide therapy
    Fioroni, F.
    Grassi, E.
    Asti, M.
    Sergi, F.
    Guidi, G.
    Filice, A.
    Versari, A.
    Iori, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S82 - S82
  • [27] Technology of DTPA and immunoglobulins conjugation and their attachment to 90Y and 177Lu radionuclides
    Rekova, M.
    Budsky, F.
    Miler, V.
    Malek, Z.
    Jedinakova-Krizova, V.
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2010, 286 (03) : 853 - 859
  • [28] Comparison of 90Y and 177Lu measurement capability in UK and European hospitals
    Fenwick, Andrew
    Baker, Michaela
    Ferreira, Kelley
    Keightley, John
    APPLIED RADIATION AND ISOTOPES, 2014, 87 : 10 - 13
  • [29] Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors A Meta-analysis
    Saravana-Bawan, Bianka
    Bajwa, Amandeep
    Paterson, John
    McEwan, Alexander J. B.
    McMullen, Todd P. W.
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 719 - 727